Lucia Masarova, M.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Lucia Masarova
Dr. Masarova is a highly motivated physician pursuing an academic, translational-research career. She has a broad knowledge, training and expertise in Oncology and Hematology. Her research includes various aspects of hematologic malignancies, with special interest in infections, immune system involvement, and influence of disease background and therapies on their outcome. During her medical training and early in her career (in Slovakia), she served as principal investigator and co-investigator of several research projects on hospital funded grants, or on a voluntary basis, exploring the impact of infectious complications on the outcome of patients with Hematologic Malignancy. Dr. Masarova has actively collaborated with researchers from other European countries and co-developed the largest Central European database of invasive fungal infections. Through these projects, Dr. Masarova has learned the importance of frequent and effective communication among projects members, and extended her knowledge in managing and analyzing medical databases, and clinical trials.
As a logical consequence of these experiences, Dr. Masarova has pursued additional postdoctoral and clinical fellowship at MD Anderson Cancer Center in Houston, Texas, USA. Here, Dr. Masarova has focused her research on Leukemias and Myeloproliferative Neoplasms under the mentorship of leading experts in Hematology, such as Srdan Verstovsek, MD, PhD; or Jorge Cortes, MD. This advanced training allowed her to further enhance research skills and gain tremendous clinical experience in treated patients with Leukemias. She also opted to take courses in research design, medical statistics and scientific writing, which significantly improved her efficiency in conducting and analyzing clinical research. During this time, Dr. Masarova completed many research projects and first-authored several manuscripts in peer-reviewed journals as well as presented her research at the world’s largest Hematologic and Oncologic Conferences. In addition to her clinical and research training, Dr. Masarova acquired leadership and administrative skills, and taught medical students and residents. Because of her medical background and experience Dr. Masarova feels well prepared to take care of patients with Hematologic Malignancies and carry out complex research projects.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2007 | Comenius University Bratislava School of Medicine, Bratislava, SVK, MD, General Medicine |
Postgraduate Training
| 2015-2017 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2015-2015 | Research Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2007-2012 | Clinical Residency, Internal Medicine, National Cancer Institute Bratislava, Klenova 1, Bratislava |
| 2007-2012 | Clinical Fellowship, Medical Oncology, National Cancer Institute, Bratislava, Klenova 1, Bratislava |
Board Certifications
| 2012 | Medical Oncology - Slovakia |
Experience & Service
Academic Appointments
Attending Physician, Department of Hematology & Transfusion Medicine, National Cancer Institute, Bratislava, 2012 - 2013
Other Appointments/Responsibilities
Sr. Research Scientist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018
Observer, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, 2014 - 2014
Research Specialist, Gerald Champion Cancer Center, Alamogordo, NM, 2013 - 2014
Honors & Awards
| 2017 | Future Leaders in Clinical Research in Hematology, Celgene |
| 2016 | Best Poster Award: Second Autotransplant in Patients with Hodgkin's Lymphoma, 6th Slovak Lymphoma Forum, Bratislava, Slovakia |
| 2016 | The Shannon Timmons Fellowship for Leukemia Research, The University of Texas MD Anderson Cancer Center |
| 2016 | Merit Achievement Award, American Society of Hematology |
| 2016 - 2017 | Best Clinical Fellow, Department of Leukemia, The University of Texas MD Anderson Cancer Center |
| 2007 | Academic Award of the Dean of the Faculty of Medicine for Excellent Study Results, Comenius University Bratislava |
Selected Publications
Peer-Reviewed Articles
- Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RK. Moving towards disease modification in polycythemia vera. Blood 142(22):1859-1870, 2023. e-Pub 2023. PMID: 37729609.
- Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
- Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. e-Pub 2023. PMID: 37699357.
- Masarova L. Momelotinib, the next JAK2 inhibitor?. Clin Adv Hematol Oncol 21(4):195-197, 2023. PMID: 37039727.
- Chifotides HT, Masarova L, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 23(4):219-231, 2023. e-Pub 2023. PMID: 36797153.
- Babakhanlou R, Masarova L, Verstovsek S. A review of essential thrombocythemia and its complications. Clin Adv Hematol Oncol 21(2):76-84, 2023. PMID: 36780473.
- Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
- Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334-S335, 2022. PMID: 36164004.
- Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334, 2022. PMID: 36164003.
- Masarova L. EXABS-116-MPN Extended Abstract: Novel Therapies for PV. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S18-S20, 2022. PMID: 36163714.
- Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(4):210-223, 2022. e-Pub 2021. PMID: 34840087.
- Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
- Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. PMID: 33885751.
- Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. PMID: 33112940.
- Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126(19):4322-4331, 2020. e-Pub 2020. PMID: 32697338.
- Bose P, Masarova L, Verstovsek S. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050168.
- Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126(7):1448-1459, 2020. e-Pub 2020. PMID: 31999850.
- Masarova L, Mesa RA, Hernández-Boluda JC, Taylor JA. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. Leuk Res 91:106338, 2020. e-Pub 2020. PMID: 32200188.
- Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, Puga RD, Alves Paiva RM, Arcila ME, Hamerschlak N, Kantarjian HM, Levine RL, Campregher PV, Rampal RK, Verstovsek S. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia 34(3):799-810, 2020. e-Pub 2019. PMID: 31628430.
- Masarova L, Cortes J, Patel K, O’Brien S, Nogueras-Gonzalez G, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia T, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour E, Kantarjian H. Long-Term Results of a Phase 2 Trial of Nilotinib 400 mg Twice Daily in Newly Diagnosed Patients With Chronic-Phase Chronic Myeloid Leukemia. Cancer:1-10, 2020.
- Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 14(4):310-327, 2019. PMID: 31228096.
- Masarova L, Verstovsek S. Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs 24(2):1-13, 2019. e-Pub 2019. PMID: 31050912.
- Masarova L, Verstovsek S. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Clin Adv Hematol Oncol 17(5):299-307, 2019. PMID: 31188809.
- Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki 60(9):1176-1185, 2019. e-Pub 2019. PMID: 31597841.
- Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97(11):2071-2080, 2018. e-Pub 2018. PMID: 29951914.
- Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
- Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
- Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109-121, 2018. e-Pub 2017. PMID: 29143068.
- Masarova L, Verstovsek S, Kantarjian H, Daver N. Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol 10(10):903-914, 2017. e-Pub 2017. PMID: 28799436.
- Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
- Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125-1131, 2017. e-Pub 2017. PMID: 28674026.
- Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
- Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv 1(14):863-866, 2017. e-Pub 2017. PMID: 29296729.
- Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 4(4):e165-e175, 2017. e-Pub 2017. PMID: 28291640.
- Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95, 2017. PMID: 28321813.
- Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol 6:30, 2017. e-Pub 2017. PMID: 29152412.
- Masarova L, Kantarjian H, Daver N.. Immune Checkpoint Approaches in AML and MDS: A Next Frontier?. The Journal of Targeted Therapies in Cancer 10:903-914, 2017.
- Chihara D,Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res 48:1-5, 2016. e-Pub 2016. PMID: 27416326.
- Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma 57(1):237-9, 2016. e-Pub 2015. PMID: 25904378.
- Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res 39(8):822-7, 2015. e-Pub 2015. PMID: 26012362.
Invited Articles
- Masarova L, Verstovsek S. Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere. J Clin Oncol:JCO2018793497. e-Pub 2018. PMID: 30346901.
Manuals, Teaching Aids, Other Teaching Publications
- Masarova L, Mego M.. Biological treatment in oncology. Via practica, 2011.
- Masarova L, Mego M. Use of biological therapy in clinical oncology, 2011.
- Masarova L. Treatment of invasive fungal diseases - 3rd Fungal Forum. Onkologia, 2010.
Other Articles
- Masarova L Mego M Biological treatment in oncology. Via practica(8):265-269, 2011.
- Masarova L, Mego M Use of biological therapy in clinical oncology. Bedeker Zdravia 3, 2011.
- Masarova L 3rd Fungal Forum. Treatment of invasive fungal diseases. Onkologia 5:304-305, 2010.
Abstracts
- Masarova L, Bose P, Pemmaraju N, Chifotides H, Zhou L, Estrov Z, Kantarjian H, Verstovsek S. Outcome of Patients with Prefibrotic Myelofibrosis from a Large Academic Center. EHA Library, 2022.
- Masarova L, Bose P, Pemmaraju N, Chifotides HT, Zhou L, Estrov Z, Kantarjian H, Verstovsek S. Characteristics of patients with myelofibrosis on ruxolitinib for three or more years. Journal of Clinical Oncology 40(16_suppl):e19082-e19082, 2022.
- Masarova L., Bose P, Pemmaraju N, Zhou L, Pierce SA, Estrov Z, Kantarjian H, Verstovsek S. Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils. Blood 138(Suppl 1), 2021.
- Masarova L, Verstovsek S, Bose P, Pemmaraju N, Cortes J, Jabbour E, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Kadia T, DiNardo C, Ravandi F, Konopleva M, Naqvi K, Sasaki K, Estrov Z, Garcia-Manero G, Bueso-Ramos C, Kantarjian H, Daver N. Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood 134(Suppl 1), 2019.
- Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. European Hematology Association, 2018.
- Masarova L, Bose P, Pemmaraju N, Estrov Z, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S.. Evaluation of Cytogenetic Stratifications in Myelofibrosis. Blood 132(Suppl 1):1763, 2018.
- Masarova L, Daver N, Kadia T, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S.. Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia - Final Results of a Prospective Phase 2 Study. American Society of Hematology. Blood 132(Suppl 1):1764, 2018.
- Masarova L, Verstovsek S, Cortes J, Pemmaraju N, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Daver N. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132(Suppl 1):352, 2018.
- Masarova L, Cortes J, Patel K, O'Brien S, Nogueras González G, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia T, Ravandi F, Borthakur G, Dellasala S, Jabbour E, Kantarjian H. Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. Blood 132(Suppl 1):3011, 2018.
- Santos F, Getta B, Masarova L , Famulare C, Schulman J, Santos Datoguia T, Goncalves G, Hamerschlak N, Kantarjian H, Levine R, Campregher P, Rampal R, Verstovsek S.. A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia/Polycythemia Vera Myelofibrosis. Blood 132(Suppl 1):1757, 2018.
- Santos F, Getta B, Masarova L, Famulare C, Schulman J, Puga R, de Melo Alves Paiva R, Hamerschlak N, Kantarjian H, Levine R, Campregher P, Rampal R, Verstovsek S.. Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia /Polycythemia Vera Myelofibrosis. Blood 132(Suppl 1):1756, 2018.
- Romano A, Palandri F, Masarova L , Bonifacio M, Polverelli N, Elli E, Iurlo A, Bergamaschi M, Benevolo G, Tieghi A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Bosi C, Crugnola M, Catani L, Scaffidi L, Cattaneo D, Vitolo U, Cuneo A, Semenzato G, Aversa F, Cavo M, Vianelli N, Bartoletti D, Scalise L, Palumbo G, Di Raimondo F, Verstovsek S.. Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. Blood Suppl 1(132):4303, 2018.
- Masarova L, Bose P, Newberry K, Abou Zahr A, Cortes J, Kantarjian H, Verstovsek S.. Correlation between blast percentage in myelofibrosis and outcomes: a single-center experience. American Society of Clinical Oncology, 2017.
- Masarova L, Cortes J, Pemmaraju N, Jabbour E, Bose P, Maro Ohanian, Zhou L, Pierce S, Romany Gergis, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S, Daver N.. Phase 2 study of Ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. American Society of Clinical Oncology:7063, 2017.
- Masarova L, Bose P, Cortes J, Kantarjian H, Verstovsek S. Do we need to re-define accelerated phase of myelofibrosis? Correlation between blast percentage in myelofibrosis and outcomes. Society of Hematologic Oncology:131, 2017.
- Masarova L, Kantarjian H, Verstovsek S.. Elevated peripheral blood (4-9%) and bone marrow blasts (5-9%) are associated with poor prognosis in patients with primary myelofibrosis as well as post-essential thrombocythemia and post-polycythemia vera myelofibrosis. International Association for Comparative Research on Leukemia and Related Diseases:131, 2017.
- Masarova L, Kantarjian H, Verstovsek S.. Validation of The Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. International Association for Comparative Research on Leukemia and Related Diseases:31, 2017.
- Masarova L, Patel K, Mallampathi S, Duose YD, Newberry JK, Cortes J, Estrov Z, Kantarjian H, Luthra R, Verstovsek S.. Correlation of Mutational Profile and Response in Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Pegylated Interferon Alfa 2a As Part of a Prospective Phase II Study. American Society of Hematology:1640, 2017.
- Masarova L, Bose P, Pemmaraju N, Daver N, Cortes J, Estrov Z, Kantarjian H, Verstovsek S.. Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. American Society of Hematology:4205, 2017.
- Boddu P, Mansurov A, Masarova L , Bose P, Patel K, Estrov Z, Kantarjian H, Verstovsek S.. Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia. American Society of Hematology:4183, 2017.
- Masarova L, Bose P, Pemmaraju N, Newberry K, Bueso-Ramos C, Cortes J, Kantarjian H,. Clinical associations of cytogenetic abnormalities in patients with primary and post-essential thrombocythemia / post-polycythemia vera myelofibrosis. American Society of Hematology:4265, 2016.
- Masarova L, Bose P, Daver N, Newberry K, Cortes J, Kantarjian H, Verstovsek S.. Cytogenetic risk stratification in primary versus post-essential thrombocythemia and post-polycythemia vera myelofibrosis. American Society of Hematology:4250, 2016.
- Masarova L, Bose P, Daver N, Newberry K, Cortes J, Kantarjian H, Verstovsek S.. Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy. American Society of Hematology:4687, 2016.
- Masarova L, Yin C. C, Cortes J., Konopleva M, Borthakur G, Newberry K, Kantarjian H, Bueso-Ramos C, Verstovsek S.. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). American Society of Hematology:4266, 2016.
- Masarova L, Bose P, Daver N, Newberry K, Cortes J, Garcia-Manero G, Kantarjian H, Verstovsek S. Clinical characteristics of patients with primary or post-polycythemia vera/post-essential thrombocytopenia myelofibrosis and deletion 13q. Society of Hematologic Oncology:114, 2016.
- Masarova L, Newberry K, Pierce S, Cortes J, Kantarjian H, Verstovsek S.. Does occurrence of other malignancy after essential thrombocythemia (ET) and polycythemia vera (PV) influence their rate of transformation to myelofibrosis (MF)?. Society of Hematologic Oncology:116, 2016.
- Masarova L, Bose P, Pemmaraju N, Daver N, Newberry K, Cortes J, Kantarjian H, Verstovsek S.. Does Therapy- Related Myelofibrosis Exist? Analysis of 1100 Myelofibrosis Cases from a Single Institution. J Clinical Oncology:34, 2016.
- Alhuraiji A, Masarova L, Bose P, Daver N, Cortes J, Pierce S, Kantarjian H, Verstovsek S.. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: a single-center experience in 1100 myelofibrosis patients. J Clinical Oncology, 2016.
- Masarova L, Verstovsek S. Co-occurrence of lymphoproliferative neoplasm and myelofibrosis. Pan-Pacific Lymphoma Conference:61, 2016.
- Masarova L, Bose P, Newberry K, Cortes J, Garcia-Manero G, Kantarjian H, Verstovsek S.. Therapy-Related Myelofibrosis does not appear to exist. Society of Hematologic Oncology:115, 2015.
- Masarova L, Daver N., Pemmaraju N, Bose P, Pierce S, Manshouri T, Cortes J, Kantarjian H, Verstovsek S.. Do patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis?. American Society of Hematology:4069, 2015.
- Masarova L, Newberry K, Daver N, Pemmaraju N, Pierce S, Cortes J, Kantarjian H, Verstovsek S.. Clinical relevance of other malignancies in patients with myelofibrosis. The 8th International Congress on Myeloproliferative Neoplasms, Myelodysplasia and Chronic Myeloid Leukemia:102, 2015.
Book Chapters
- Verstovsek S, Bose P, Masarova L, Amin H. Philadelphia chromosome negative myeloproliferative neoplasms. In: The MD Anderson Manual of Medical Oncology. 4th edition, 2023.
- Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. In: Adv Exp Med Biol, 97-116, 2018.
Letters to the Editor
- Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106: 894-898, 2021.
- Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, Asatiani E, Daver NG. Treatment of The Myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 Inhibitor. Ann Oncol 29: 1880-1882.
- Masarova L, Wang W, Newberry KJ, Kantarjian H, Verstovsek S. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood 128: 877-80, 2016.
Patient Reviews
CV information above last modified July 12, 2024